Marcus W. Brazier

发表

A manganese-superoxide dismutase/catalase mimetic extends survival in a mouse model of human prion disease.

C. Masters, S. Doctrow, S. Collins, 2008, Free radical biology & medicine.

Manganese Binding to the Prion Protein*

F. Marken, J. H. Viles, David R. Brown, 2008, Journal of Biological Chemistry.

Antioxidant and Metal Chelation-Based Therapies in the Treatment of Prion Disease

A. G. Wedd, S. Collins, Marcus W. Brazier, 2014, Antioxidants.

Sublethal Concentrations of Prion Peptide PrP106–126 or the Amyloid Beta Peptide of Alzheimer's Disease Activates Expression of Proapoptotic Markers in Primary Cortical Neurons

C. Masters, A. Hill, K. Beyreuther, 2001, Neurobiology of Disease.

Correlative studies support lipid peroxidation is linked to PrPres propagation as an early primary pathogenic event in prion disease

C. Masters, A. Hill, R. Cappai, 2006, Brain Research Bulletin.

Extended period of asymptomatic prion disease after low dose inoculation: Assessment of detection methods and implications for infection control

C. Masters, A. Hill, G. Klug, 2005, Neurobiology of Disease.

Mouse galectin‐1 inhibits the toxicity of glutamate by modifying NR1 NMDA receptor expression

David R. Brown, Marcus W. Brazier, S. Hesketh, 2006, The European journal of neuroscience.

Metal attenuating therapies in neurodegenerative disease

David R. Brown, A. G. Wedd, S. Collins, 2011, Expert review of neurotherapeutics.

High affinity copper binding by stefin B (cystatin B) and its role in the inhibition of amyloid fibrillation

David R. Brown, E. Žerovnik, Marcus W. Brazier, 2006, The FEBS journal.

Detection of prion epitopes on PrPc and PrPsc of transmissible spongiform encephalopathies using specific monoclonal antibodies to PrP

A. Hill, G. Multhaup, R. Cappai, 2005, Immunology and cell biology.

Human prion diseases: cause, clinical and diagnostic aspects.

Marcus W. Brazier, R. Knight, S. Collins, 2004, Contributions to microbiology.

Manganese chelation therapy extends survival in a mouse model of M1000 prion disease

C. Masters, A. Hill, I. Volitakis, 2010, Journal of neurochemistry.

Therapeutic interventions ameliorating prion disease

C. Masters, S. Collins, Marcus W. Brazier, 2009, Expert review of anti-infective therapy.

Dynamics of a truncated prion protein, PrP(113–231), from 15N NMR relaxation: Order parameters calculated and slow conformational fluctuations localized to a distinct region

J. H. Viles, David R. Brown, S. Abdelraheim, 2009, Protein science : a publication of the Protein Society.

NMR characterization of the pH 4 beta-intermediate of the prion protein: the N-terminal half of the protein remains unstructured and retains a high degree of flexibility.

Christopher E. Jones, J. H. Viles, David R. Brown, 2007, The Biochemical journal.

Microdissection of Alzheimer Brain Tissue for the Determination of Focal Manganese Accumulation

Marcus W. Brazier, 2017 .

Prion protein does not redox-silence Cu2+, but is a sacrificial quencher of hydroxyl radicals.

J. H. Viles, David R. Brown, S. Abdelraheim, 2007, Free radical biology & medicine.

Diverse fibrillar peptides directly bind the Alzheimer’s amyloid precursor protein and amyloid precursor-like protein 2 resulting in cellular accumulation

C. Masters, G. Multhaup, K. Beyreuther, 2003, Brain Research.

Quinacrine does not prolong survival in a murine Creutzfeldt‐Jakob disease model

C. Masters, A. Hill, V. Lewis, 2002, Annals of neurology.

Immunotherapeutic approaches in prion disease: progress, challenges and potential directions.

S. Collins, Anthony R. White, Marcus W. Brazier, 2013, Therapeutic delivery.

Human Prion Diseases: Cause, Clinical and Diagnostic Aspects

Marcus W. Brazier, R. Knight, S. Collins, 2001 .